T. Ş CERRAHOĞLU, A GÜLER, H ŞİRİN, N ÇELEBİSOY

İnme ve kanser birlikteliği: 30 olgunun analizi

Amaç: Bu çalışmada kliniğimize serebrovasküler hastalık tanısı ile yatan etiyolojik taramada kanser varlığı ya da öyküde kanser birlikteliği saptanan hastaların kanser tipleri, olası inme nedeni ve diğer demografik verileri açısından incelenerek, elde edilen sonuçların mevcut literatür bilgileri eşliğinde tartışılması amaçlanmıştır. Gereç ve Yöntem: Çalışmamıza 2008-2012 yılları arasında SVH tanısıyla Ege Üniversitesi Tıp Fakültesi Nöroloji Yoğun Bakım Ünitesi ve Servisinde yatırılarak izlenen, kanser birlikteliği saptanan hastalar alındı. Hastalar demografik veriler, mevcut kanser tipi ve patolojisi, metastaz varlığı, uygulanmış olan tedavi tipi (radyoterapi, kemoterapi), kür varlığı, inme açısından risk faktörlerinin varlığı, kanser ve inme arası zamansal ilişki açısından değerlendirildi. Bulgular: 2008-2012 yılları arasında SVH tanısıyla Ege Üniversitesi Tıp Fakültesi Nöroloji Yoğun Bakım Ünitesi ve Servisinde yatırılarak izlenen ve kanser birlikteliği saptanan 30 hasta (10 kadın/ 20 erkek)çalışmaya alındı. SVH için başka risk faktörü olmayan, sadece kanser birlikteliği olan 8 (%26,66) hasta bulundu. Kanser varlığı için SVH için herhangi başka risk faktörü olmayan bu hastaların 3’ü Akciğer adenokarsinomu, 1’i akciğer küçük hücreli kanseri, 1’i parosteoal osteosarkom, 1’i serviks müsinöz adenokarsinom, 1’i mide adenokarsinoma ve 1’i mesane tümörüne sahipti. Sonuç: İnme etyolojisi araştırılırken klasik inme risk faktörlerinin yanı sıra çok çeşitli mekanizmalarla tromboza yatkınlık yaratan gizli kanserlerin araştırmalarda akılda bulundurulması gerektiği unutulmamalıdır.

Stroke and cancer association: Analysis of 30 patients

Aim: In this study, we examined patients hospitalized with a diagnosis of cerebrovascular disease, who had a history of cancer or determined cancer during the etiologic scanning, in terms of the cancer type, possible causes of stroke and demographic data. We aimed to discuss our results in the light of pertinent literature. Materials and Methods: Patients who had been diagnosed with cerebrovascular disease and had a medical history of cancer, and had been hospitalized in the Ege University Medical School Neurological Intensive Care Unit between 2008-2012 were included in our study. For these patients, we examined demographic data, cancer type and pathology, the presence of metastasis, applied treatment (radiotherapy, chemotherapy), the presence of a cure for cancer, other possible causes of stroke, the relationship between cancer and the time of the stroke. Results: In our study, the total number of patients who had a diagnosis of cerebrovascular disease and medical history of cancer was 30 (10 women, 20 men). In eight patients (26.6%), there was no possible risk factor which could be thought to be the cause of stroke, except cancer. From those eight patients, three patients had lung adenocarsinoma, one had small cell lung cancer, one periosteal cancer, one had cervical adenocarcinoma, one gastric adenocarcinoma and one had bladder cancer. Conclusion: While investigating the etiology of stroke as well as classical risk factors, it must be kept in mind that there can be other rare etiologies of stroke such as hidden cancers can cause stroke by means of thrombosis by a variety of mechanisms.

PDF

___

1. Dipasco PJ, Misra S, Koniaris LG, Moffat FL Jr. Thrombophilic state in cancer, part I: Biology, incidence, and risk factors. J Surg Oncol 2011;104(3):316-22.
2. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 1985;64:16-35.
3. Donati MB.Thrombosis and cancer: Trousseau syndrome revisited. Best Pract Res Clin Haematol 2009;22(1):3-8.
4. Chen PC, Muo CH, Lee YT, Yu YH, Sung FC. Lung cancer and incidence of stroke: A population-based cohort study. Stroke 2011;42(11):3034-9.
5. Ready NE, Dudek AZ, Pang HH, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 2011;20(33):4436-41.
6. Rosell J, Nordenskjöld B, Bengtsson NO, et al. Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial. Br J Cancer 2011;104(6):899-902.
7. Heidemann C, Boeing H, Pischon T, Nöthlings U, Joost HG, Schulze MB. Association of a diabetes risk score with risk of myocardial infarction, stroke, specific types of cancer, and mortality: A prospective study in the European Prospective Investigation into Cancer and Nutrition (EPIC) - Potsdam cohort. Eur J Epidemiol 2009;24(6):281-8.
8. Azulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 2011;60(6):1244-50.
9. Chen L, Li Y, Gebre W, Lin JH. Myocardial and cerebral infarction due to nonbacterial thrombotic endocarditis as an initial presentation of pancreatic adenocarcinoma. Arch Pathol Lab Med 2004;128(11):1307-8.
10. Giray S, Sarica FB, Arlier Z, Bal N. Recurrent ischemic stroke as an initial manifestation of an concealed pancreatic adenocarcinoma: Trousseau's syndrome. Chin Med J 2011;124(4):637-40.
11. Pérez-Lázaro C, Santos S, Morales-Rull JL, et al. Stroke as the first manifestation of a concealed pancreatic neoplasia. Rev Neurol 2004;29;38(4):332-5.
12. Limper AH, Prakash UB, Kokmen E, Callahan MJ. Cardiopulmonary metastatic lesions of osteosarcoma and associated cerebral infarction. Mayo Clin Proc 1988;63(6):592-5.
13. Scott AS, Parr LA, Johnstone PAS. Risk of cerebrovascular events after neck and supraclavicular radiotherapy: A systematic review. Radiother Oncol 2009;90(2):163-5.